ClinicalTrials.gg
CompletedNCT01325701Updated Mar 31, 2017Results posted

Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

A Phase 2 interventional study of ibrutinib in Diffuse Large Cell B-lymphoma, sponsored by Pharmacyclics LLC.. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-31.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse — 3 open to participants now, 10 under way, 2 of them phase 3. ibrutinib · Lymphoma, Large B-Cell, Diffuse.

Enrollment
9th of 26
78 · median 44
Started
2011
the only one that year
Phase 2
8 of 26
1 open now
Registered
1st of 26
by date
Lead sponsor
2 of 26
Pharmacyclics LLC.

Among the 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 9th largest by enrollment, is the only one that started in 2011, is one of 8 in phase 2, and was the 1st registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

3 of the 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of ibrutinib (PCI-32765) in relapsed/refractory de novo activated B-cell (ABC) and germinal-cell B-Cell (GCB) Diffuse Large B-cell Lymphoma (DLBCL).

Read the detailed description

The primary objectives of this study were to evaluate the efficacy of ibrutinib administered at 560 mg once per day in relapsed or refractory de novo ABC and GCB DLBCL, and to evaluate the efficacy of ibrutinib administered at 840 mg once per day in relapsed or refractory de novo ABC DLBCL.

The secondary objective was to evaluate the safety and tolerability of a fixed daily oral dosing regimen of ibrutinib in relapsed/refractory de novo DLBCL.

03

Conditions studied

  • Diffuse Large Cell B-lymphoma

Keywords

  • PCI-32765
  • Lymphoma, B-Cell
  • Bruton's Tyrosine Kinase
  • Non Hodgkin's Lymphoma
  • Germinal Center B-Cell
  • Activated B-Cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women ≥ 18 years of age.
  2. performance status ≤ 2.
  3. confirmed de novo DLBCL
  4. Subjects must have available tissue for central pathology review to be eligible. Treatment Group 2: Subjects will be eligible if they have the non-GCB phenotype, as confirmed by Central IHC testing by the Hans method.
  5. disease, defined as either: 1) recurrence of disease after a CR, or 2) PR, SD, or progressive disease (PD) at completion of the treatment regimen preceding entry to the study (residual disease): Subjects must have previously received an appropriate treatment regimen. Subjects who have not received HDT/ must be ineligible for HDT/ASCT
  6. Treatment Group 1: Subjects must have ≥ 1 measurable (> 2 cm in longest dimension) disease sites on CT scan. Treatment Group 2: Subjects must have ≥ 1 measurable (> 1.5 cm in longest dimension) disease sites on CT scan.

Exclusion criteria

Exclusion Criteria:

  1. Transformed DLBCL or DLBCL with coexistent histologies (eg, FL or MALT).
  2. Primary mediastinal (thymic) large B-cell lymphoma.
  3. Known central nervous system lymphoma. In addition, for subjects in Treatment Group 2, known is exclusionary.
  4. Certain exclusions on prior therapy
  5. Major surgery within 2 weeks of first dose of study drug.
  6. Any of the following laboratory abnormalities:

    1. ANC \< 0.75 x 10\^9/L. Treatment Group 2: Eligible subjects must be independent of growth factor support for 7 days prior to the screening lab tests.
    2. count \< 50 x 10\^9/L independent of transfusion support. Treatment Group 2 only: Eligible subjects must be independent of transfusion support for 7 days prior to the screening lab tests.
    3. or ALT ≥ 3.0 x (ULN)
    4. Creatinine > 2.0 x ULN
    5. Treatment Group 2 only: \< 8.0 g/dL
    6. Treatment Group 2 only: Total > 1.5 x ULN
  7. Requires or has received anticoagulation treatment with warfarin or equivalent Vitamin K antagonists (eg, phenprocoumon)
  8. Treatment Group 2: Requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor
  9. Treatment Group 2: Known bleeding diathesis, eg, von Willebrand's disease, hemophilia.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    PCI-32765: 560 mg

    Treatment Group 1: Subjects received 560 mg of ibrutinib once daily, on a continuous basis.

    Drug: ibrutinib

  • Experimental
    PCI-32765: 840 mg

    Treatment Group 2: Subjects received 840 mg of ibrutinib once daily, on a continuous basis.

    Drug: ibrutinib

Interventions

  • ibrutinib is an inhibitor of BTK

    Also known as: PCI-32765, Imbruvica

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With an Overall Response to Study Drug

    The primary endpoint of the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR), according to the revised International Working Group Criteria for non-Hodgkin's lymphoma (Cheson et al, 2007), as assessed by the investigator.

    Time frame: The median follow up time on the study for all treated participants is 1.7 months (range 0.1- 32.3 months)

Secondary outcomes

  1. Number of Patients With Adverse Events as a Measure of Safety and Tolerability

    Participants will be followed until progression of the disease or start of another anticancer treatment. The clinical database captured all AEs from baseline through end of treatment. Treatment Emergent AEs were collected pre-dose, at the beginning of each cycle and 30 days post last dose of study drug, unless related to study drug.

    Time frame: Adverse events determined to be related to study drug are collected from first dose until study exit (approximately 3 years).

  2. Ibrutinib and Its Metabolite (PCI-45227) AUC0-24h After Repeat Dosing of PCI-32765

    Treatment Group 1 PK collection schedule: Cycle 1 Day 1: Pre-dose, 1, 2, 4, 7, and 24 hours post-dose Cycle 1 Day 8: Pre-dose, 1, 2, 4, 7, and 24 hours post-dose Cycle 1 Day 15: Pre-dose and 2 hours post-dose Cycle 1 Day 22: Pre-dose and 2 hours post-dose Treatment Group 2 PK collection schedule: Cycle 1 Day 8: Pre-dose, 1, 2, 4 and 7 hours post-dose Cycle 1 Day 15: Pre-dose and 2 hours post-dose Cycle 1 Day 22: Pre-dose and 2 hours post-dose Cycle 3 Day 1: Pre-dose, 1, 2, and 4 hours post-dose

    Time frame: Performed during the first month of receiving study drug.

07

Results

Posted Feb 16, 2017
Limitations and caveats
PCI-32765:840 mg:8 subjects were enrolled and followed through their 1st response assessment. Due to a lack of positive responses observed, enrollment was terminated for futility. Response rate should not be generalized due to small sample size.

Participant flow

Participant flow — Overall Study
MilestonePCI-32765: 560 mgPCI-32765: 840 mg
Started708
Completed495
Not completed213
Withdrew: Adverse event120
Withdrew: Protocol violation10
Withdrew: Physician decision22
Withdrew: Withdrawal by subject21
Withdrew: Rollerover extension study40

Outcome measures

PrimaryPercentage of Patients With an Overall Response to Study Drug

The primary endpoint of the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR), according to the revised International Working Group Criteria for non-Hodgkin's lymphoma (Cheson et al, 2007), as assessed by the investigator.

Time frame:
The median follow up time on the study for all treated participants is 1.7 months (range 0.1- 32.3 months)
Reported as:
Number · percentage of participants
Percentage of Patients With an Overall Response to Study Drug
percentage of participantsPCI-32765: 560 mgPCI-32765: 840 mg
Percentage of Patients With an Overall Response to Study Drug24.312.5
SecondaryNumber of Patients With Adverse Events as a Measure of Safety and Tolerability

Participants will be followed until progression of the disease or start of another anticancer treatment. The clinical database captured all AEs from baseline through end of treatment. Treatment Emergent AEs were collected pre-dose, at the beginning of each cycle and 30 days post last dose of study drug, unless related to study drug.

Time frame:
Adverse events determined to be related to study drug are collected from first dose until study exit (approximately 3 years).
Reported as:
Number · participants
Number of Patients With Adverse Events as a Measure of Safety and Tolerability
participantsPCI-32765: 560 mgPCI-32765: 840 mg
Number of Patients With Adverse Events as a Measure of Safety and Tolerability708
SecondaryIbrutinib and Its Metabolite (PCI-45227) AUC0-24h After Repeat Dosing of PCI-32765

Treatment Group 1 PK collection schedule: Cycle 1 Day 1: Pre-dose, 1, 2, 4, 7, and 24 hours post-dose Cycle 1 Day 8: Pre-dose, 1, 2, 4, 7, and 24 hours post-dose Cycle 1 Day 15: Pre-dose and 2 hours post-dose Cycle 1 Day 22: Pre-dose and 2 hours post-dose Treatment Group 2 PK collection schedule: Cycle 1 Day 8: Pre-dose, 1, 2, 4 and 7 hours post-dose Cycle 1 Day 15: Pre-dose and 2 hours post-dose Cycle 1 Day 22: Pre-dose and 2 hours post-dose Cycle 3 Day 1: Pre-dose, 1, 2, and 4 hours post-dose

Time frame:
Performed during the first month of receiving study drug.
Reported as:
Mean · ng*h/mL
Ibrutinib and Its Metabolite (PCI-45227) AUC0-24h After Repeat Dosing of PCI-32765
ng*h/mLPCI-32765: 560 mgPCI-32765: 840 mg
PCI-32765 - Day 81285 ± 9711337 ± 1556
PCI-45227 (Metabolite)- Day 81485 ± 9481671 ± 1147

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PCI-32765: 560 mg—40/70 (57.1%)70/70 (100%)
PCI-32765: 840 mg—3/8 (37.5%)8/8 (100%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventPCI-32765: 560 mgPCI-32765: 840 mg
DehydrationMetabolism and nutrition disorders0/702/8
Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/702/8
Febrile neutropeniaBlood and lymphatic system disorders1/701/8
Hypercalcaemia of malignancyEndocrine disorders0/701/8
PancreatitisGastrointestinal disorders0/701/8
Non-cardiac chest painGeneral disorders0/701/8
PneumoniaInfections and infestations7/701/8
Enterobacter sepsisInfections and infestations0/701/8
HypotensionVascular disorders0/701/8
Respiratory failureRespiratory, thoracic and mediastinal disorders4/700/8
Most frequent other events
Showing 10 of 251
Most frequent other events
EventPCI-32765: 560 mgPCI-32765: 840 mg
NauseaGastrointestinal disorders24/704/8
FatigueGeneral disorders30/700/8
DiarrhoeaGastrointestinal disorders28/703/8
Alanine aminotransferase increasedInvestigations6/703/8
InsomniaPsychiatric disorders7/703/8
AnaemiaBlood and lymphatic system disorders20/701/8
Non-cardiac chest painGeneral disorders0/702/8
Aspartate aminotransferase increasedInvestigations7/702/8
HypoalbuminaemiaMetabolism and nutrition disorders11/702/8
DehydrationMetabolism and nutrition disorders5/702/8

Baseline characteristics

A total of 78 subjects were enrolled: 70 in PCI-32765: 560 mg , and 8 in PCI-32765: 840 mg . All subjects received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)PCI-32765: 560 mgPCI-32765: 840 mgTotal
<=18 years000
Between 18 and 65 years38442
>=65 years32436
Age, Continuous
Age, Continuous(Years)PCI-32765: 560 mgPCI-32765: 840 mgTotal
Mean62.5 ± 13.4064.4 ± 13.9662.7 ± 13.38
Sex: Female, Male
Sex: Female, Male(Participants)PCI-32765: 560 mgPCI-32765: 840 mgTotal
Female20222
Male50656
Region of Enrollment
Region of Enrollment(participants)PCI-32765: 560 mgPCI-32765: 840 mgTotal
United States70878
08

Study locations

15 sites
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • National Cancer Institute
    Bethesda, Maryland 20892-1203, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Long Island Jewish Medical Center
    New Hyde Park, New York 11042, United States
  • New York University
    New York, New York 10016, United States
  • Weill Medical College of Cornell University
    New York, New York 10021, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • University of Rochester School of Medicine and Dentistry
    Rochester, New York 14642, United States
  • The Ohio Sate university
    Columbus, Ohio 43210, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Univerity of Washington
    Seattle, Washington 98109, United States
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
09

References and documents

Publications

  • Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015 Aug;21(8):922-6. doi: 10.1038/nm.3884. Epub 2015 Jul 20. PubMed 26193343 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2011
First posted
Mar 30, 2011
Start
May 2011
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
Feb 16, 2017
Last update
Mar 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01325701
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Mar 30, 2011
Start date
May 2011
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Feb 16, 2017
Last update
Mar 31, 2017

Study contacts

Darrin Beaupre, MD
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion